Substantial inter-individual and limited intra-individual genomic diversity among tumors from men with metastatic prostate cancer

[1]  Chao Lu,et al.  Retrospective study , 2016, Medicine.

[2]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[3]  Wei Yuan,et al.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.

[4]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[5]  M. Nykter,et al.  The Evolutionary History of Lethal Metastatic Prostate Cancer , 2015, Nature.

[6]  Andrew Menzies,et al.  Analysis of the Genetic Phylogeny of Multifocal Prostate Cancer Identifies Multiple Independent Clonal Expansions in Neoplastic and Morphologically Normal Prostate Tissue , 2015, Nature Genetics.

[7]  Jun Luo,et al.  Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study , 2015, Science Translational Medicine.

[8]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[9]  Yu Cao,et al.  Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing , 2014, Science.

[10]  Z. Szallasi,et al.  Spatial and temporal diversity in genomic instability processes defines lung cancer evolution , 2014, Science.

[11]  Ming Yu,et al.  Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer , 2014, Nature Communications.

[12]  Chris Sander,et al.  Copy number alteration burden predicts prostate cancer relapse , 2014, Proceedings of the National Academy of Sciences.

[13]  Wennuan Liu,et al.  Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma , 2013, Clinical Cancer Research.

[14]  D. Zheng,et al.  Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade , 2013, Cell.

[15]  W. Isaacs,et al.  Tracking the clonal origin of lethal prostate cancer. , 2013, The Journal of clinical investigation.

[16]  Raul Rabadan,et al.  The integrated landscape of driver genomic alterations in glioblastoma , 2013, Nature Genetics.

[17]  H. Aburatani,et al.  Integrated molecular analysis of clear-cell renal cell carcinoma , 2013, Nature Genetics.

[18]  K. Kaestner,et al.  Mash1 expression is induced in neuroendocrine prostate cancer upon the loss of Foxa2 , 2013, The Prostate.

[19]  Johan Lindberg,et al.  The mitochondrial and autosomal mutation landscapes of prostate cancer. , 2013, European urology.

[20]  K. Ovaska,et al.  FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. , 2013, Cancer research.

[21]  Martin J. Aryee,et al.  DNA Methylation Alterations Exhibit Intraindividual Stability and Interindividual Heterogeneity in Prostate Cancer Metastases , 2013, Science Translational Medicine.

[22]  K. Cibulskis,et al.  Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. , 2012, The Journal of clinical investigation.

[23]  M. Rubin,et al.  Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. , 2013, Neoplasia.

[24]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[25]  Tony T. Huang,et al.  The Fanconi anemia pathway in replication stress and DNA crosslink repair , 2012, Cellular and Molecular Life Sciences.

[26]  A. Sivachenko,et al.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.

[27]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[28]  R. Arceci.  Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing , 2012 .

[29]  J. Uhm.  Clonal selection drives genetic divergence of metastatic medulloblastoma , 2012 .

[30]  Stephen J. Salipante,et al.  Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers , 2011, Proceedings of the National Academy of Sciences.

[31]  D. Schindler,et al.  Fanconi Anemia Core Complex Gene Promoters Harbor Conserved Transcription Regulatory Elements , 2011, PloS one.

[32]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[33]  J. Cuzick,et al.  Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. , 2011, The Lancet. Oncology.

[34]  K. Pienta,et al.  Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. , 2011, Genome research.

[35]  M. Nowak,et al.  Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.

[36]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[37]  R. Cardiff,et al.  Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. , 2010, Cancer cell.

[38]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[39]  J. Isaacs,et al.  The Prostate 69 : 1724 ^ 1729 ( 2009 ) TissueCultureMedia SupplementedWith 10 % Fetal Calf SerumContains aCastrate Levelof Testosterone , 2009 .

[40]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[41]  Jun Luo,et al.  Copy Number Analysis Indicates Monoclonal Origin of Lethal Metastatic Prostate Cancer , 2009, Nature Medicine.

[42]  J. Clements,et al.  Direct Progesterone Receptor and Indirect Androgen Receptor Interactions with the Kallikrein-Related Peptidase 4 Gene Promoter in Breast and Prostate Cancer , 2009, Molecular Cancer Research.

[43]  T. Golub,et al.  Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. , 2008, Journal of the National Cancer Institute.

[44]  Kenichi Yoshida,et al.  Systems Biology-Based Identification of Crosstalk between E2F Transcription Factors and the Fanconi Anemia Pathway , 2007, Gene Regulation and Systems Biology.

[45]  Lawrence D. True,et al.  Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases , 2007, Clinical & Experimental Metastasis.

[46]  W. Sellers,et al.  Lineage dependency and lineage-survival oncogenes in human cancer , 2006, Nature Reviews Cancer.

[47]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[48]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[49]  Hubert Vesselle,et al.  Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. , 2003, Human pathology.

[50]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[51]  N. Hay,et al.  Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. , 1998, Molecular endocrinology.

[52]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[53]  D. Grignon,et al.  High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. , 1994, In vivo.

[54]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.